Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy of olaparib when given in combination with paclitaxel compared with
paclitaxel alone as defined by progression-free survival (PFS), in all patients with
recurrent and metastatic gastric cancer who progress following first-line therapy.